Stock price, Nova Wax, a major US vaccine xo company Soaring more than 7% in after-hours trading this morning. After the company announced the start of testing a vaccine against COVID-19. The last term in England
Novavax will conduct a trial to study the efficacy of the vaccine on 10,000 participants xo aged 18-84 years after the vaccine was selected in that early clinical trial. Antibodies can be produced at high enough levels to fight COVID-19.
The Nova Wax expects It would take four to six weeks to obtain data from a final trial to apply for a vaccine xo approval in the UK, the European Union and other countries. Previously The company expects to apply for approval in the United States in December.
In addition, Nova Wax is expected. Two billion doses of the anti-COVID vaccine will be produced per year when the vaccine becomes effective in mid-2021.
